Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

15 Jan 2007 12:52

Phytopharm PLC15 January 2007 Phytopharm plc Annual Information Update Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 28 December 2006, the following information has been published or made available to the public during the 12 months ended 12 January 2007, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets. For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulations, we confirm that to the best of our knowledge, information relating to 'Holdings in Company' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement, but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances. 1. Announcements made via Regulatory Information Services All documents listed below were published via a regulatory information service on the dates indicated: Date of publication Title 10 January 2007 Director/PDMR shareholding10 January 2007 Director/PDMR shareholding 9 January 2007 Board changes19 December 2006 Notification of total voting rights10 November 2006 Director/PDMR shareholding 8 November 2006 Preliminary results for the year ended 31 August 2006 1 November 2006 Block listing interim review27 October 2006 Notification of results18 September 2006 Block listing interim review 5 September 2006 Board changes21 July 2006 Board appointment 5 June 2006 Board appointment19 May 2006 Holding(s) in company11 May 2006 Director/PDMR shareholding11 May 2006 Director/PDMR shareholding 8 May 2006 Interim results 3 May 2006 Block listing interim review27 April 2006 Holding(s) in company27 April 2006 Holding(s) in company26 April 2006 Advisor appointment24 April 2006 Product launch10 April 2006 Research update30 March 2006 Notice of results17 March 2006 Block listing interim review30 January 2006 Second price monitoring extension30 January 2006 Price monitoring extension24 January 2006 Results of AGM 2. Documents despatched to shareholders The following documents have been despatched by the Company to holders of its securities during the year: 27 December 2006 - Annual Report 2006 1 June 2006 - Interim Report 2006 3. Documents field at Companies House The Company has submitted the following Filings to Companies House: 11 January 2007 Form 288(a) Appointment of Director Mr Piers Morgan11 January 2007 Form 288(b) Terminating appointment of Director - Dr Richard Dixey 5 December 2006 Form 363 Annual Return 6 September 2006 Form 288(b) Terminating appointment of Director - Dr Trevor Flanagan 6 September 2006 Form 288(b) Terminating appointment of Director - Mr Gordon Stevens24 July 2006 Form 288(a) Appointment of Director - Dr Peter Blower 8 June 2006 Form 288(a) Appointment of Director - Mr Alexander Morrison24 January 2006 Registration of special resolutions passed at AGM Copies of these documents can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ (Telephone 0870 3333 636, email at enquiries@companies-house.gov.uk) or, if you are a registered user, through Companies House Direct at www.companies-house.gov.uk The Company's annual report and accounts 2006 (published on 28 December 2006) and Interim Report 2005 (published on 1 June 2006) can be found on the Company's website as can the Interim Results announcement for the six months ended 28 February 2006 (published on 8 May 2006) and the Preliminary Results Announcement (published on 8 November 2006), The Company's website is www.phytopharm.com. Copies of all documents referred to above are also available for inspection at the Company's registered office (Corpus Christi House, 9 West Street, Godmanchester, Cambs PE29 2HY, United Kingdom) during normal business hours or by request from the Company Secretary. For further information, please contact: Zoe McGowan, Company Secretary Phytopharm plc Tel No: +44 (0)1480 437697 Further information, about Phytopharm can be found on the Company's website www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.